CKI 7 dihydrochloride: Streamlining Casein Kinase 1 Inhibition Workflows

Principle and Setup: Precision Targeting of Casein Kinase 1

CKI 7 dihydrochloride (N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide dihydrochloride) has emerged as a gold-standard Casein kinase 1 (CK1) inhibitor for dissecting serine/threonine kinase-driven signaling networks. Through competitive binding at the ATP site of CK1 isoforms, this compound enables researchers to interrogate phosphorylation cascades central to circadian rhythm regulation, Wnt/β-catenin signaling, DNA repair, and cancer metastasis (source). Supplied by APExBIO at ≥98% purity and available in 1mg and 5mg formats, CKI 7 dihydrochloride is optimized for both biochemical and cellular applications, with solubility up to 17.93 mg/ml in DMSO and 7.17 mg/ml in water (source: product_spec).

Stepwise Experimental Workflows and Enhanced Protocols

To extract maximal mechanistic insight and reproducibility when using CKI 7 dihydrochloride in cell signaling or cancer biology assays, consider the following evidence-based and workflow-driven protocol parameters:

Protocol Parameters

• Cellular inhibition assay | 10–20 μM | Inhibition of CK1 in Wnt signaling pathway | Empirically determined to robustly suppress β-catenin phosphorylation and downstream target gene expression in NSCLC and colorectal cancer cell lines | source
• Incubation time | 1–24 hours | Apoptosis assay using CK1 inhibitors | Short-term exposure (1–4 h) for acute pathway deactivation; longer incubation (24 h) to assess sustained effects on cell viability and apoptosis | source
• Storage temperature | -20°C | Cancer biology research with CK1 inhibitors | Ensures compound stability for up to 12 months; avoid repeated freeze-thaw cycles | product_spec
• Working solution stability | Use within 12 hours (in DMSO or water) | Circadian rhythm regulation studies | Prevents compound degradation and loss of potency during signaling assays | workflow_recommendation
• Vehicle control concentration | ≤0.2% DMSO (v/v) | All cell-based assays | Minimizes vehicle-induced cytotoxicity and data variability | workflow_recommendation

Key Innovation from the Reference Study

The recent study published in the International Journal of Biological Macromolecules (paper) uncovers the MAPK10/KRT16/RNF213 axis as a crucial suppressor of non-small cell lung cancer (NSCLC) metastasis. Specifically, MAPK10 phosphorylates keratin 16 (KRT16), triggering its RNF213-mediated ubiquitination and proteasomal degradation. This mechanistic insight not only highlights phosphorylation as a regulatory switch in metastatic progression but also underscores the value of selective kinase inhibition for pathway dissection. For researchers, this translates into practical guidance: pairing CKI 7 dihydrochloride treatment with phospho-proteomics or immunoblotting for KRT16 phosphorylation and degradation offers a direct readout of CK1 signaling and its consequences for cell migration and invasion. Furthermore, integrating CK1 inhibition into metastatic assays can help delineate the interplay between Wnt signaling and cytoskeletal regulation in cancer models.

Protocol Enhancements: From Signal Dissection to Pathway Crosstalk

CKI 7 dihydrochloride has become indispensable for:

• Wnt/β-catenin pathway mapping: By inhibiting CK1, researchers can block β-catenin phosphorylation and nuclear accumulation, which is central to gene transcription associated with proliferation and metastasis (source).
• Circadian biology: CK1 isoforms (e.g., CK1δ/ε) regulate PER protein stability; CKI 7 dihydrochloride allows precise temporal modulation in circadian rhythm regulation studies (product_spec).
• Apoptosis and viability assays: Combining CKI 7 dihydrochloride with Annexin V/PI staining or caspase activity assays reveals how CK1-dependent phosphorylation events influence cell fate (source: workflow_recommendation).

Advanced Applications, Comparative Advantages, and Interlinked Insights

Compared to less selective kinase inhibitors, CKI 7 dihydrochloride offers enhanced specificity for CK1 isoforms, enabling cleaner interpretation of signaling outcomes. In cancer biology research with CK1 inhibitors, its use facilitates the dissection of pathway crosstalk—especially between Wnt signaling, cytoskeletal remodeling, and cellular adhesion, as highlighted in the MAPK10/KRT16 study (paper).

For further reading, three articles provide expanded perspectives:

• "CKI 7 dihydrochloride: Precision Targeting of CK1 in Cancer Pathways" complements this guide by detailing CK1 inhibition’s mechanistic bridge to Wnt signaling and metastasis assays.
• "CKI 7 dihydrochloride (SKU B4936): Practical Solutions" offers scenario-driven troubleshooting and best practices for maximizing assay reproducibility, reinforcing the protocol recommendations herein.
• "CKI 7 dihydrochloride: Precision Modulation of CK1 in Advanced Research" extends these concepts to circadian and metastasis models, highlighting translational opportunities and experimental pitfalls.

Collectively, these resources underscore CKI 7 dihydrochloride’s position as a versatile, cell-permeable CK1 inhibitor for signaling pathway research, particularly in the context of cancer metastasis and circadian regulation.

Troubleshooting and Optimization Tips

• Compound solubilization: Given limited aqueous solubility, first dissolve CKI 7 dihydrochloride in DMSO (≤17.93 mg/ml), then dilute into pre-warmed cell culture medium to achieve working concentrations. Avoid exceeding 0.2% DMSO final concentration to minimize cytotoxicity (source: product_spec).
• Assay timing: For rapid pathway deactivation, use 1–4 h incubations; extended incubations (24 h) may reveal secondary effects, such as altered cell survival or compensatory signaling (source).
• Phospho-protein readouts: Pair CKI 7 dihydrochloride treatment with phospho-specific antibodies for β-catenin, PER, or KRT16 to directly measure CK1-dependent phosphorylation events and link them to functional outcomes (paper).
• Controls: Always include vehicle controls and, where possible, a non-CK1-targeted kinase inhibitor as a negative control to distinguish on-target effects (workflow_recommendation).
• Batch-to-batch consistency: Source CKI 7 dihydrochloride from trusted suppliers such as APExBIO to ensure purity and performance (source: product_spec).

Future Outlook: Pathway Mapping and Personalized Cancer Research

The elucidation of the MAPK10/KRT16/RNF213 axis in NSCLC metastasis (paper) exemplifies the power of pathway-centric research using selective kinase inhibitors. CKI 7 dihydrochloride is poised to drive further advances in:

• Personalized biomarker discovery, by integrating CK1 inhibition with patient-derived xenograft or organoid models.
• Mechanistic dissection of cell adhesion and cytoskeletal remodeling in metastatic progression.
• Temporal mapping of circadian protein networks and their links to cell cycle and DNA repair.

However, as highlighted in the literature, CK1 inhibition must be interpreted within the broader context of pathway redundancy and compensatory mechanisms, necessitating careful assay design and multi-modal readouts (source).

Conclusion

CKI 7 dihydrochloride, especially when sourced from APExBIO, is a cornerstone reagent for scientists seeking to unravel the complexities of CK1-mediated signaling in cancer, circadian biology, and beyond. By adhering to data-driven protocols, leveraging advanced readouts, and learning from recent breakthroughs in metastatic signaling, researchers can maximize the impact and reproducibility of their findings. For detailed product specifications and ordering, visit the CKI 7 dihydrochloride product page.